The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus

Q3 Medicine

Endocrine and Metabolic Science Pub Date : 2025-03-17 DOI:10.1016/j.endmts.2025.100230

To Anh Tan Le , An Viet Tran , Son Kim Tran , Chau Minh Tran , Dang Khoa Dang Tran , Duy Huu Duong , Toan Hoang Ngo

{"title":"The effectiveness of Rosuvastatin in controlling LDL-C and non-HDL-C levels in hypertensive patients with or without diabetes mellitus","authors":"To Anh Tan Le , An Viet Tran , Son Kim Tran , Chau Minh Tran , Dang Khoa Dang Tran , Duy Huu Duong , Toan Hoang Ngo","doi":"10.1016/j.endmts.2025.100230","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>LDL-C and non-HDL-C are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy in hypertensive patients with or without diabetes mellitus is essential.</div></div><div><h3>Objectives</h3><div>This study aims to compare the efficacy of Rosuvastatin 20 mg in controlling LDL-C and non-HDL-C in hypertensive patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.</div></div><div><h3>Results</h3><div>In hypertensive patients without diabetes (n = 54; 42.9 %), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4 %) compared to those with diabetes (n = 72; 57.1 %). After 12 weeks of Rosuvastatin 20 mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-C and non-HDL-C levels (p < 0.001). The treatment targets for LDL-C were achieved by 27.8 % of diabetic patients and 20.4 % of non-diabetic patients, while the targets for non-HDL-C were achieved by 40.3 % of diabetic patients and 41.5 % of non-diabetic patients. History of stroke and coronary artery disease was significantly associated with increased LDL-C and non-HDL-C in both pre-and post-treatment in both groups.</div></div><div><h3>Conclusion</h3><div>The utilization of Rosuvastatin 20 mg has shown efficacy in ameliorating elevated LDL-C and non-HDL-C levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20 mg aids in better control of LDL-C and non-HDL-C compared to the hypertensive group with diabetes.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"18 ","pages":"Article 100230"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine and Metabolic Science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666396125000160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

LDL-C and non-HDL-C are contributing risk factors in the development of cardiovascular disease and stroke, exacerbating hazardous cardiovascular events. Rosuvastatin is a widely used statin globally, and a thorough assessment of its efficacy in hypertensive patients with or without diabetes mellitus is essential.

Objectives

This study aims to compare the efficacy of Rosuvastatin 20 mg in controlling LDL-C and non-HDL-C in hypertensive patients with and without diabetes.

Methods

A cross-sectional descriptive study on 126 primary hypertensive patients (72 hypertensive patients with diabetes and 54 hypertensive patients without diabetes) treated with Rosuvastatin based on cardiovascular risk stratification according to SCORE to assess the efficiency of achieving treatment targets.

Results

In hypertensive patients without diabetes (n = 54; 42.9 %), the average age was higher (63.52 ± 8.68 years) and predominantly female (70.4 %) compared to those with diabetes (n = 72; 57.1 %). After 12 weeks of Rosuvastatin 20 mg treatment, non-diabetic patients exhibited more significant improvements in lipid profiles, notably marked decreases in LDL-C and non-HDL-C levels (p < 0.001). The treatment targets for LDL-C were achieved by 27.8 % of diabetic patients and 20.4 % of non-diabetic patients, while the targets for non-HDL-C were achieved by 40.3 % of diabetic patients and 41.5 % of non-diabetic patients. History of stroke and coronary artery disease was significantly associated with increased LDL-C and non-HDL-C in both pre-and post-treatment in both groups.

Conclusion

The utilization of Rosuvastatin 20 mg has shown efficacy in ameliorating elevated LDL-C and non-HDL-C levels in primary hypertensive patients. Specifically, in the hypertensive group without diabetes, Rosuvastatin 20 mg aids in better control of LDL-C and non-HDL-C compared to the hypertensive group with diabetes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊